Research suggests that a new type of antipsychotic, xanomeline and trospium chloride (Cobenfy), is associated with significant improvements in cognitive symptoms among people with schizophrenia.

After a year in 2024 with the St. Louis Cardinals at the age of 37 that was certainly good enough to draw another short term contract as a starter, Lynn is not pigeon holed to the bullpen if he ...

It's astonishing to consider that with the current market cap, covered entirely by cash plus the anticipated royalties and milestones from Cobenfy, investors are essentially getting ownership in ...

In September 2024, the Food and Drug Administration (FDA) approved Cobenfy, a drug to treat schizophrenia that analysts believe could generate a whopping $7.5 billion in revenue at its peak.

While the launch of new products like Cobenfy is seen positively, Flynn believes that additional growth drivers are necessary to counterbalance the expected losses and to justify the company’s ...

David Risinger’s rating is based on the impressive launch performance of Bristol-Myers Squibb’s Cobenfy, which is showing strong sales momentum since its introduction for schizophrenia treatment.

You may want to think twice before doing your skincare routine today. Skincare brand First Aid Beauty recently issued a voluntary recall of 2,756 jars of its bestselling Ultra Repair Cream.

Veteran stars LeBron James, Stephen Curry and Nikola Jokić also among the 10 starters for the 2025 NBA All-Star Game. Official release • Get NBA League Pass TODAY • NBA All-Star 2025 ...

Michael Strahan Opens Up About Daughter’s Brain Cancer and the Words He’ll Never Forget: ‘I Want to Live’ (Exclusive) Through his daughter Isabella’s toughest times, after her brain tumor was removed ...

(Pediatric Research) Could the largest market for the new schizophrenia drug xanomeline and trospium chloride (Cobenfy) be in Alzheimer's disease psychosis, agitation, and cognition? Bristol Myers ...

Meanwhile, Bristol-Myers Squibb (BMY) sees potential in its schizophrenia drug, Cobenfy, as a future Alzheimer's treatment.